Rexahn Pharmaceuticals, Inc. (RNN)

Oncology Corporate Profile

Stock Performance

2.3800
-0.0700

3 Month Stock History Chart

HQ Location

15245 Shady Grove Road, Suite 455
Rockville, MD 20850

Company Description

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer, central nervous system (CNS) disorders and other unmet medical needs. The Company's lead cancer candidate, Archexin (formerly named RX-0201), is currently in Phase II clinical trials for patients with pancreatic cancer and renal cell carcinoma (RCC), an abnormal growth of cells lining the tubules of the kidney. Multiple indications are possible.

Website: http://www.rexahn.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
RX-3117DNA synthesis inhibitorPancreatic cancerII
Archexin® / RX-0201Akt-1 inhibitorRenal cell carcinoma (RCC)II
Supinoxin® / RX-5902phosphorylated-p68 (P-p68) inhibitorTriple negative Breast cancerII
RX-3117DNA synthesis inhibitorBladder cancerI
RX-3117DNA synthesis inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.rexahn.com

Recent News Headlines

Rexahn Pharmaceuticals Initiates Stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer

9/12/2016 04:58 pm

(Yahoo! Finance) Sept 12, 2016 - Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced it has initiated stage 2 of the Phase Ib/IIa clinical trial with the novel oral anti-cancer agent RX-3117 in relapsed or refractory pancreatic cancer patients.

Use of Complementary, Alternative Medicine Affects Initiation of Chemotherapy

5/13/2016 06:05 am

(Columbia University) May 12, 2016 - Women with early-stage breast cancer for whom chemotherapy was indicated and who used dietary supplements and multiple types of complementary and alternative medicine (CAM) were less likely to start chemotherapy than nonusers of alternative therapies according to new research.

Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral Anti-Cancer Therapeutic RX-3117 in the Treatment of Pancreatic and Bladder Cancer

3/29/2016 04:40 pm

(Morningstar) Mar 29, 2016 - Rexahn Pharmaceuticals, Inc. today announced that it has enrolled the first patient in its Phase Ib/IIa clinical trial of a the novel oral anti-cancer agent, RX-3117, in patients with relapsed and refractory pancreatic cancer and advanced bladder cancer.

Scientists Create World's Largest Catalog of Human Genomic Variation

10/1/2015 12:02 pm

(NIH) Sept 30, 2015 - An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases.

Immunotherapy Combination Nivolumab Plus Ipilimumab Receives FDA Approval for Metastatic Melanoma

10/1/2015 12:01 pm

(MSK/On Cancer blog) Oct 1, 2015 - Today, the US Food and Drug Administration (FDA) approved the immunotherapy combination nivolumab (Opdivo®) plus ipilimumab (Yervoy®) for use in patients with metastatic melanoma.

Cancer Immunotherapy: The Cutting Edge Gets Sharper

10/1/2015 12:01 pm

(Scientific American) Oct 1, 2015 - Scientists try to understand why some patients get better and others don’t.

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

10/1/2015 12:01 pm

(Merck) Oct 1, 2015 - Merck and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.

Precision Medicine Will (Eventually) Lower Cancer Care Costs

10/1/2015 12:01 pm

(Forbes) Oct 1, 2015 - Sky-high medication prices are emerging as a political issue.

Call for Britain to Over-Ride Patents on Roche Cancer Drug

10/1/2015 12:01 pm

(Reuters) Oct 1, 2015 - A group of patients and campaigners has called on Britain's health minister to over-ride patents protecting Roche's expensive breast cancer drug Kadcyla to allow for the import or manufacture of cut-price copies.

Why Doctors Are Rethinking Breast-Cancer Treatment

10/1/2015 12:01 pm

(TIME Magazine) Oct 12, 2015 Issue - Too much chemo. Too much radiation. And way too many mastectomies.

XOMA Licenses TGFb Immuno-Oncology Program to Novartis for Up to $517M+

10/1/2015 12:01 pm

(GEN News) Oct 1, 2015 - XOMA said today it has exclusively licensed global development and commercialization rights to its preclinical anti-transforming growth factor-beta (TGFb) antibody program in immuno-oncology to Novartis.

Nivolumab in Combination with Ipilimumab

10/1/2015 12:00 pm

(FDA.gov) Oct 1, 2015 - On September 30, 2015, the U. S. Food and Drug Administration granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma.

Doctors Often Overtreat with Radiation in Late-Stage Lung Cancer

10/1/2015 12:00 pm

(University of Illinois) Sept 30, 2015 - Almost half of patients with advanced lung cancer receive more than the recommended number of radiation treatments to reduce their pain, according to a new study published in the Journal of the National Cancer Institute.

Investigational Therapeutic KW-0761 Efficiently Depletes Immune System–suppressing Treg Cells

10/1/2015 12:00 pm

(AACR) Oct 1, 2015 - Immune cells called Tregs, which can inhibit anticancer immune responses, were efficiently eliminated from the blood of patients with lung or esophageal cancer by treatment with the investigational therapeutic antibody KW-0761, according to results of a phase Ia clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Study Shows New 'Driver' to Assess Cancer Patient Survival and Drug Sensitivity

10/1/2015 12:00 pm

(MD Anderson) Oct 1, 2015 - Cancer specialists have long looked at genetic mutations and DNA copy changes to help predict patient survival and drug sensitivity.

Treatment-Free Intervals in Ovarian Cancer Not Linked to Initial Response

10/1/2015 12:00 pm

(RPCI) Sept 29, 2015 - Roswell Park study provides evidence that platinum-based chemotherapies are superior.

UNC Lineberger Researcher Partnering to Develop Rapid Oral HPV Test

10/1/2015 12:00 pm

(UNC Lineberger CCC) Sept 28, 2015 - A UNC Lineberger Comprehensive Cancer Center researcher is working to fight a growing type of head and neck cancer by partnering to develop a rapid oral test for HPV, a virus linked to cancer.

Scientists Discover How to Trap Cancer Cells before They Spread

10/1/2015 12:00 pm

(Cancer Research UK) Oct 1, 2015 - Researchers have discovered a new way to potentially ‘fence in’ a tumour and help stop cancer cells spreading.

Disrupting Tumor Cell “Microenvironment” Suggests a New Way to Treat a Prevalent Childhood Leukemia

6/8/2015 11:05 am

(NYU Langone) June 8, 2015 - Blocking a specific protein receptor decimates leukemia cells.

Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors

7/18/2014 04:20 pm

(MarketWatch) July 18, 2014 - Rexahn Pharmaceuticals, Inc. today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin™ (RX-5902) in cancer patients with solid tumors.

Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors

7/18/2014 06:02 am

(MarketWatch) July 18, 2014 - Rexahn Pharmaceuticals, Inc. today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin™ (RX-5902) in cancer patients with solid tumors.

Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine

3/7/2014 05:54 pm

(TheStreet) Mar 7, 2014 - Welcome back to the Biotech Stock Mailbag. Let's get started with an email from Dapo A., who wants an update on Exact Sciences:

Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine

3/7/2014 11:05 am

(TheStreet) Mar 7, 2014 - Welcome back to the Biotech Stock Mailbag. Let's get started with an email from Dapo A., who wants an update on Exact Sciences:

Rexahn Initiates Phase IIa Clinical Trial of Archexin® in Patients with Metastatic Renal Cell Carcinoma

1/14/2014 05:51 pm

(Yahoo! Finance) Jan 14, 2014 - Rexahn Pharmaceuticals, Inc. announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin® in patients with metastatic renal cell carcinoma (RCC).

Rexahn Initiates Phase IIa Clinical Trial of Archexin® in Patients with Metastatic Renal Cell Carcinoma

1/14/2014 11:05 am

(Yahoo! Finance) Jan 14, 2014 - Rexahn Pharmaceuticals, Inc. announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin® in patients with metastatic renal cell carcinoma (RCC).

Rexahn Pharmaceuticals Announces Teva Will Not Exercise its Option to License RX-3117

8/28/2013 03:52 pm

(CNBC) Aug 28, 2013 - Rexahn Pharmaceuticals announced today that Teva Pharmaceutical Industries has decided, for strategic reasons, not to exercise its option to license RX-3117 from Rexahn.

Rexahn Pharmaceuticals Announces Teva Will Not Exercise its Option to License RX-3117

8/28/2013 10:05 am

(CNBC) Aug 28, 2013 - Rexahn Pharmaceuticals announced today that Teva Pharmaceutical Industries has decided, for strategic reasons, not to exercise its option to license RX-3117 from Rexahn.

Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors

8/7/2013 03:58 pm

(Fort Mill Times) Aug 7, 2013 - Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company announced today the commencement of patient dosing with SupinoxinTM (RX-5902) in a Phase I clinical trial designed to study safety and efficacy in patients with solid cancer tumors.

Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors

8/7/2013 10:05 am

(Fort Mill Times) Aug 7, 2013 - Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company announced today the commencement of patient dosing with SupinoxinTM (RX-5902) in a Phase I clinical trial designed to study safety and efficacy in patients with solid cancer tumors.

Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform

7/17/2013 04:59 pm

(Rexahn Pharmaceuticals) July 17, 2013 - Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore (UMB) for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems (NPDCS).

Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform

7/17/2013 11:05 am

(Rexahn Pharmaceuticals) July 17, 2013 - Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore (UMB) for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems (NPDCS).

Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis

5/17/2013 07:01 am

(Sanofi) May 17, 2013 - Sanofi announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups.

Bio-Path Holdings to Expand Development of Liposomal Grb-2 into Two Additional Indications: Triple Negative and Inflammatory Breast Cancers

12/6/2012 03:01 pm

(4-traders) Dec 5, 2012 - Bio-Path Holdings, Inc. today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.